Today, Regeneron Pharmaceuticals Inc. (REGN) PT Set at $450.00 by Canaccord Genuity

Today, Regeneron Pharmaceuticals Inc. (REGN) PT Set at $450.00 by Canaccord Genuity

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has been assigned a $450.00 target price by investment analysts at Canaccord Genuity in a research report issued to clients and investors on Sunday. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Canaccord Genuity’s target price suggests a potential upside of 13.02% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Leerink Swann set a $511.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, August 6th. RBC Capital Markets reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday, August 6th. Roth Capital reissued a “buy” rating and set a $520.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. Brean Capital reissued a “buy” rating and set a $489.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. Finally, Vetr cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $419.76 target price for the company. in a research note on Monday, July 11th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $468.87.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.06% on Friday, hitting $398.16. The stock had a trading volume of 282,742 shares. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $565.68. The stock has a 50 day moving average price of $381.52 and a 200-day moving average price of $389.29. The company has a market cap of $41.74 billion, a price-to-earnings ratio of 58.09 and a beta of 1.79.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, November 4th. The biopharmaceutical company reported $3.13 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.73 by $0.40. Regeneron Pharmaceuticals had a return on equity of 21.51% and a net margin of 16.52%. The business earned $1.22 billion during the quarter, compared to analysts’ expectations of $1.29 billion. During the same period in the previous year, the firm posted $3.47 earnings per share. The company’s revenue was up 7.3% on a year-over-year basis. On average, equities analysts expect that Regeneron Pharmaceuticals will post $11.73 earnings per share for the current year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction on Monday, November 14th. The stock was sold at an average price of $450.00, for a total transaction of $956,250.00. Following the sale, the director now owns 15,125 shares in the company, valued at approximately $6,806,250. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Arthur F. Ryan sold 2,000 shares of the stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $429.34, for a total value of $858,680.00. Following the sale, the director now owns 36,500 shares in the company, valued at approximately $15,670,910. The disclosure for this sale can be found here. Company insiders own 10.40% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of REGN. Jennison Associates raised its position in shares of Regeneron Pharmaceuticals by 10.9% in the third quarter. Jennison Associates now owns 1,922,133 shares of the biopharmaceutical company’s stock worth $894,061,000 after buying an additional 189,407 shares in the last quarter. Braun Stacey Associates acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth $9,070,000. Terra Nova Asset Management raised its position in shares of Regeneron Pharmaceuticals by 9.7% in the third quarter. Terra Nova Asset Management now owns 5,945 shares of the biopharmaceutical company’s stock worth $2,765,000 after buying an additional 524 shares in the last quarter. Gerstein Fisher raised its position in shares of Regeneron Pharmaceuticals by 27.7% in the third quarter. Gerstein Fisher now owns 900 shares of the biopharmaceutical company’s stock worth $419,000 after buying an additional 195 shares in the last quarter. Finally, EQIS Capital Management raised its position in shares of Regeneron Pharmaceuticals by 49.5% in the fourth quarter. EQIS Capital Management now owns 5,032 shares of the biopharmaceutical company’s stock worth $2,732,000 after buying an additional 1,666 shares in the last quarter. 68.45% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Related posts

Leave a Comment